Switch View
© PR Newswire
22.09.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders
News Preview
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA).
Shareholders who purchased shares of SVRA during the class period listed are encouraged to conta...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Lantheus Holdings, Inc. Class Action: The Gross Law Firm Reminds Lantheus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 10, 2025 - LNTH
News Preview
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH).
Shareholders who purchased shares of LNTH during the class period listed are encoura...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
Shareholders of LifeMD, Inc. Should Contact The Gross Law Firm Before October 25, 2025 to Discuss Your Rights - LFMD
News Preview
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD).
Shareholders who purchased shares of LFMD during the class period listed are encouraged to cont...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
22.09.2025
ISIN: US02155H2004
Altimmune Inc
ALT
LISTED
NASDAQ
The Gross Law Firm Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
News Preview
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
Shareholders who purchased shares of ALT during the class period listed are encouraged to con...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
22.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights - REPL
News Preview
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL).
Shareholders who purchased shares of REPL during the class period listed are encourage...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
Investors who lost money on Nutex Health Inc. (NUTX) should contact The Gross Law Firm about pending Class Action - NUTX
News Preview
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nutex Health Inc. (NASDAQ: NUTX).
Shareholders who purchased shares of NUTX during the class period listed are encouraged to...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Lost Money on Cytokinetics, Incorporated(CYTK)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
News Preview
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK).
Shareholders who purchased shares of CYTK during the class period listed are enco...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
Class Action Filed Against Semler Scientific, Inc. (SMLR) - October 28, 2025 Deadline to Join - Contact The Gross Law Firm
News Preview
NEW YORK, Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Semler Scientific, Inc. (NASDAQ: SMLR).
Shareholders who purchased shares of SMLR during the class period listed are encoura...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US64125C1099
Neurocrine Biosciences Inc
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
News Preview
SAN DIEGO, Sept. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 2 SAVITRI™ study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator (NBI-10...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs....
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US9467841055
Waystar Holding Corp.
WAY
LISTED
NASDAQ
Waystar Joins S&P SmallCap 600 Index
News Preview
Inclusion underscores durable growth, innovation leadership, and long-term shareholder value
LEHI, Utah and LOUISVILLE, Ky., Sept. 22, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that it has joined the S&P SmallCap 600® Index, effective before the market opens on...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US02155H2004
Altimmune Inc
ALT
LISTED
NASDAQ
INVESTOR ALERT: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025
News Preview
PHILADELPHIA, Sept. 22, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of Altimmune between August 10, 2023 through June 25, 2025 (the "Cl...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
22.09.2025
ISIN: US74051N1028
Premier Inc
PINC
LISTED
NASDAQ
PINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Premier, Inc. Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Premier, Inc. (NASDAQ: PINC) to an affiliate of Patient Square Capital for $28.25 in cash per share is fair to Premier shareholders.
Halper Sadeh encourages Premier shareholders to click here to learn more about their legal rights and options or contact Daniel Sa...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US59267L1070
Metsera, Inc.
MTSR
LISTED
NASDAQ
MTSR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Metsera, Inc. Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Metsera, Inc. (NASDAQ: MTSR) to Pfizer Inc. is fair to Metsera shareholders. Under the terms of the proposed transaction, Metsera shareholders will receive $47.50 per share in cash at closing, plus a non-transferable contingent value right entitling holders to pote...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US74834L1008
Quest Diagnostics Inc
DGX
LISTED
NYSE
Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer
News Preview
SECAUCUS, N.J. and NEW BRUNSWICK, N.J., Sept. 22, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize p...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US03528H1095
Anixa Biosciences, Inc.
ANIX
LISTED
NASDAQ
Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
News Preview
Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and Prevention
Comprehensive Results, Supported by U.S. Department of Defense Funding, to Inform FDA Discussions and Advance Phase 2 Development Plans
SAN JOSE, Calif., Sept. 22, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: GB0009895292
AstraZeneca PLC
AZN
LISTED
LSE
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
News Preview
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate canc...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: GB0009895292
AstraZeneca PLC
AZN
LISTED
LSE
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
News Preview
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate canc...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: GB0009895292
AstraZeneca PLC
AZN
LISTED
LSE
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
News Preview
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate canc...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US22407B1089
Coya Therapeutics, Inc.
COYA
LISTED
NASDAQ
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis
News Preview
The ALSTARS Trial is a well powered randomized, multi-center, double-blind, placebo-controlled, 24-week study of COYA 302 in people with Amyotrophic Lateral Sclerosis (ALS)
Patients completing the initial 24-week treatment will be invited to participate in a 24-week blinded extension period, during which all participants will receive COYA 302
Th...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US68236V3024
ETHZilla Corporation
ETHZ
LISTED
NASDAQ
ETHZilla Announces $350 Million Add-On Convertible Debenture Investment and Provides Business Update
News Preview
PALM BEACH, Fla., Sept. 22, 2025 /PRNewswire/ -- ETHZilla Corporation (Nasdaq: ETHZ) ("ETHZilla" or the "Company"), today announced a $350 million convertible debenture by an institutional investment partner.
Convertible Debenture...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US8342033094
Soleno Therapeutics Inc
SLNO
LISTED
NASDAQ
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO
News Preview
NEW YORK, Sept. 22, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting f...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: GB0009895292
AstraZeneca PLC
AZN
LISTED
LSE
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
News Preview
BOSTON, Sept. 22, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by d...
Themefolio
Profiler
Peergroup
© Newsfile
22.09.2025
ISIN: US29415V1098
Envoy Medical, Inc.
COCH
LISTED
NASDAQ
Envoy Medical Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
News Preview
White Bear Lake, Minnesota--(Newsfile Corp. - September 22, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,908,402 shares of its C...
Themefolio
Profiler
Peergroup
© Newsfile
22.09.2025
ISIN: CA78471G1000
SOL Global Investments Corp.
SOL
LISTED
CSE
SOL Global CEO Davide Marcotti Charts Strategic Growth Path with International Investor Outreach
News Preview
Toronto, Ontario--(Newsfile Corp. - September 22, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") is pleased to provide an update under the leadership of Chief Executive Officer Davide Marcotti, who was appointed on June 3, 2025. Since his appointment, Mr. Marcotti has driven a ser...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US7140461093
Revvity Inc
RVTY
LISTED
NYSE
Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems
News Preview
Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity’s established Pin-pointTM base editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit.
This new Pin-point configuration allows for inc...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: IE00B4Q5ZN47
Jazz Pharmaceuticals PLC
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
News Preview
20 abstracts presented across World Sleep and Psych Congresses showcase Jazz's leadership in sleep medicine
Novel results from the Phase 4 DUET trial underscore the significance of appropriate treatment options in adults with narcolepsy or idiopathic hypersomnia
For U.S. media and investors only
DUBLIN, Sept. 22, 2025 /PRNewswire/ -- Jazz Pharmac...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US38341P1021
Gossamer Bio Inc
GOSS
LISTED
NASDAQ
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
News Preview
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralut...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
News Preview
Incyte (Nasdaq:INCY) announces that Dave Gardner has been appointed Executive Vice President and Chief Strategy Officer (CSO) effective today, September 22, 2025. In his new role, Mr. Gardner will serve as a key member of the Executive Leadership Team and be responsible for the Company’s strategy and business development.
"Dave possesses a uniqu...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US15102K1007
Celcuity Inc
CELC
LISTED
NASDAQ
Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress
News Preview
MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from the Phase 3 VIKTORIA-1 trial has been selected for an oral presentation at the upcoming European So...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US59935P2092
Milestone Scientific Inc
MLSS
LISTED
XASE
Milestone Scientific Appoints Dr. Dawood Sayed to Board of Directors to Advance Commercial and Clinical Strategy in Pain Management
News Preview
Appointment strengthens Board expertise as Milestone Scientific drives commercial expansion and payer adoption of CompuFlo® in interventional pain management Appointment strengthens Board expertise as Milestone Scientific drives commercial expansion and payer adoption of CompuFlo® in interventional pain management...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received
News Preview
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the expiration of the 45-day “window shop” period under the terms of the previously announced merger agreement with affiliates of Alcon (SIX/NYSE: ALC). The “window shop” peri...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US69404D1081
Pacific Biosciences of California Inc
PACB
LISTED
NASDAQ
PacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes
News Preview
Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screening Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screening...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US2197981051
QuidelOrtho Corp
QDEL
LISTED
NASDAQ
QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use
News Preview
SAN DIEGO, Sept. 22, 2025 /PRNewswire/ -- Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of innovative in vitro diagnostic technologies, is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)–cleared rapid...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US1266501006
CVS Health Corp
CVS
LISTED
NYSE
Aetna Expands Clinical Collaboration Program to Enhance Support for Hospitals and Provide Personalized Member Care
News Preview
Aetna Clinical Collaboration Program on-track to implement in ten hospitals by end of 2025 Early indicators show high member engagement with program projected to reduce 30-day readmissions and length of hospital stay HARTFORD, Conn., Sept. 22, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announced it will scale the Aetna...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US4576693075
Insmed Inc
INSM
LISTED
NASDAQ
Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
News Preview
—Data from Phase 2b Study of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Arterial Hypertension to be Presented at Late-Breaking ALERT Session—
—New Analysis from Phase 3 ASPEN Trial Examines Efficacy and Safety of Brensocatib in Japanese Patients with Non-Cystic Fibrosis Bronchiectasis by Reduction of Exacerbation History— ...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: CA39986R1064
Grown Rogue International Inc.
GRIN
LISTED
CSE
Grown Rogue Acquires the Minority Interest in Illinois Subsidiary
News Preview
Increases Ownership from 70% to 100% in Illinois Cultivation Project
MEDFORD, Ore., Sept. 22, 2025 /CNW/ - Grown Rogue International Inc. ("Grown Rogue" or the "Company") (CSE: GRIN) (OTC: GRUSF), a flower-forward cannabis company combining craft values with disciplined execution, today announced it has completed the acquisition of the 30% minori...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US31447E1055
Femasys Inc
FEMY
LISTED
NASDAQ
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
News Preview
Addition strengthens FemSperm family of products and enables gynecologists to offer complete in-office sperm handling for FemaSeed Intratubal Insemination Addition strengthens FemSperm family of products and enables gynecologists to offer complete in-office sperm handling for FemaSeed Intratubal Insemination...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US30063P1057
Exact Sciences Corp
EXAS
LISTED
NASDAQ
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, is teaming up with actor and horror icon Matthew Lillard to encourage people 45 and older to get screened for colorectal cancer—the nation’s second leading cause of cancer-related death.1
This press release features multimedia. View the full release...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US4622221004
Ionis Pharmaceuticals Inc
IONS
LISTED
NASDAQ
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. Zilganersen 50 mg demonstrated statistically significant and...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US0758871091
Becton Dickinson and Co
BDX
LISTED
NYSE
BD and Henry Ford Health Sign Pharmacy Automation Partnership to Revolutionize Medication Storage and Prescription Delivery
News Preview
FRANKLIN LAKES, N.J., Sept. 22, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a pharmacy automation partnership with Henry Ford Health to develop the health system pharmacy of the future, with an initial focus on a robotic solution that will enable patients to pic...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
News Preview
Pfizer Inc. (NYSE: PFE) and Metsera, Inc. (NASDAQ: MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portf...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF WESLEY BAMBURG AS ITS NEW CHIEF OPERATING OFFICER
News Preview
HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments in 11 states and primary care-centric, risk-bearing physician networks, today announced the appoint...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: CH0334081137
CRISPR Therapeutics AG
CRSP
LISTED
NASDAQ
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
News Preview
ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical stage biotech company developing innovative small...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US0044685008
Achieve Life Sciences, Inc.
ACHV
LISTED
NASDAQ
Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD
News Preview
New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challenges New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challenges...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US4579852082
Integra Lifesciences Holdings Corp
IART
LISTED
NASDAQ
Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer
News Preview
Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: CA64119M1059
Netramark Holdings Inc
AIAI
LISTED
CSE
NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
News Preview
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a new collaboration focused on gliobl...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US74051N1028
Premier Inc
PINC
LISTED
NASDAQ
Premier, Inc. Announces Definitive Agreement to Be Acquired by Patient Square Capital in Transaction Valued at $2.6 Billion
News Preview
Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-driven health care improvement company, today announced that it has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital (“Patient Square”).
Under the terms of the agreement, which has been unanimously approved by Premier’s Boa...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: CA48213Y1079
Jushi Holdings Inc.
JUSH
LISTED
CSE
Jushi Holdings Inc. Announces Favorable Modifications to Existing Manassas, VA Mortgage
News Preview
Company received $4,000,000 of additional loan proceeds...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US0017441017
AMN Healthcare Services Inc
AMN
LISTED
NYSE
AMN Healthcare Launches $400.0 Million Offering of Senior Notes
News Preview
DALLAS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), announced today that its wholly owned subsidiary, AMN Healthcare, Inc., intends to make a private offering of $400.0 million aggregate principal amount of senior unsecured notes due 2031, subject to market and other conditions. The 2031 Notes will be guaranteed...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US21833P3010
Corbus Pharmaceuticals Holdings Inc
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
News Preview
KOL Panel to Discuss Data from Dose Optimization Clinical Trial of CRB-701 KOL Panel to Discuss Data from Dose Optimization Clinical Trial of CRB-701...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US2214133058
Cosmos Health Inc
COSM
LISTED
NASDAQ
Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue
News Preview
Cosmos Health commences U.S. operations with its Sky Premium Life brand, supported by local manufacturing capabilities. Anticipates strong cash flow....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US15678C1027
Ceribell, Inc.
CBLL
LISTED
NASDAQ
Medtech Leader Erica Rogers Joins Ceribell Board of Directors
News Preview
Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies Accomplished innovator and healthcare executive brings proven strategic leadership and expertise in scaling high-growth healthcare companies...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: US8523123052
STAAR Surgical Co
STAA
LISTED
NASDAQ
Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company’s Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
News Preview
Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR”) (NASDAQ:STAA), today announced its opposition to the Company’s proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025.
Yunqi Capital re...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
ISIN: DE000BAY0017
Bayer AG
BAYN
LISTED
XETR
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
News Preview
Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for PD. At the same time, first European participants have been randomized in REGENERATE-PD, a Phase II...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: AU000000SPL0
Starpharma Holdings Ltd
SPL
LISTED
ASX
Starpharma Announces a Collaboration and License Agreement with Genentech
News Preview
MELBOURNE, Australia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Starpharma (ASX: SPL, US OTC: SPHRY), an innovative Australian biotechnology company, today announced the signing of a collaboration and license agreement with Genentech, a member of the Roche Group, to develop potential cancer therapies that leverage Starpharma’s proprietary DEP® drug deli...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US45826J1051
Intellia Therapeutics Inc
NTLA
LISTED
NASDAQ
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
News Preview
Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting up to three years of patient follow-up and additional insight into ATTRv-PN disease-relevant measures Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
News Preview
PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clinical trials oral presentation, one oral presentation, and three poster sessions will be shared at the Heart Fail...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US98419J2069
XOMA Royalty Corp
XOMA
LISTED
NASDAQ
XOMA Royalty Declares Quarterly Preferred Stock Dividends
News Preview
XOMA Royalty announces October 2025 dividend...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US55287L1017
MBX Biosciences, Inc.
MBX
LISTED
NASDAQ
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
News Preview
Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE)...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
